Dextromethorphan

Generic Name: Dextromethorphan

Brand Names: Auvelity, Benylin DM, Bromfed DM, Broncotron, Cepacol Sore Throat Plus Cough, Cheracol D, Children's Nyquil Cold and Cough, Chloraseptic Sore Throat + Cough, Coricidin Hbp Chest Congestion, Coricidin Hbp Cough and Cold, Creomulsion, DM, Dayquil Cough, Delsym, Delsym Cough Plus Chest Congestion DM, Delsym Cough Plus Soothing Action, Delsym Cough Relief Plus Soothing Action, Despec Reformulated Jun 2008, Diabetic Tussin DM, Dimetapp Long Acting Cough Plus Cold, Diphen, G-zyncof, Mucinex Children's Cough, Mucinex Cough, Mucinex DM, Nuedexta, Nyquil Cough, Pediacare Children's Cough and Congestion, Promethazine DM, Robafen Cough, Robafen DM, Robitussin 12 Hour Cough Relief, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Robitussin Nighttime Cough DM, Robitussin Pediatric Cough & Cold LA, Robitussin Pediatric Cough Suppressant, Safetussin DM, Safetussin PM, Scot-tussin DM, Scot-tussin Diabetic CF, Scot-tussin Sugar Free DM, Sudafed PE Children's Cold & Cough, Triaminic Day Time Cold & Cough, Tusnel Diabetic

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₅NO

CAS Number: 125-71-3

Unique Ingredient Identifier: 7355X3ROTS

Background: Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.

Dextromethorphan was granted FDA approval before 3 December 1957.

Indication: Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicated in the treatment of pseudobulbar affect.

Associated Conditions: Allergic cough, Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Allergies, Coughing caused by Bronchitis, Coughing caused by Flu caused by Influenza, Fever, Flu caused by Influenza, Headache, Irritative cough, Itching of the nose, Itching of the throat, Major Depressive Disorder (MDD), Nasal Congestion, Pseudobulbar Affect (PBA), Rhinorrhoea, Sneezing, Cold or flu syndrome, Upper respiratory symptoms, Watery itchy eyes

Associated Therapies: Airway secretion clearance therapy, Bronchodilation, Oropharyngeal antisepsis

Clinical Trials

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dextromethorphan HBr
Drug: GC4419

First Posted Date: 2019-01-04

Last Posted Date: 2019-06-19

Lead Sponsor: Galera Therapeutics, Inc.

Target Recruit Count: 13

Registration Number: NCT03792971

Locations: 🇺🇸
Inventiv Health Clinical - Research Pharmacy Unit, Miami, Florida, United States

Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.

Phase 4

Completed

Conditions: Acute Bronchitis

Interventions: Dietary Supplement: Honey 30 g (full tablespoon)
Other: Usual clinical practice
Drug: Dextromethorphan 15 milligrams
Drug: Ipratropium Bromide 20Micrograms Inhaler

First Posted Date: 2018-11-13

Last Posted Date: 2022-08-30

Lead Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Target Recruit Count: 668

Registration Number: NCT03738917

Locations: 🇪🇸
Singuerlin Health Center, Santa Coloma De Gramenet, Catalonia, Spain
🇪🇸
Balaguer Health Center, Balaguer, Catalonia, Spain
🇪🇸
La Marina Health Center, Barcelona, Catalonia, Spain

and more 9 locations

Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder

Phase 1

Completed

Conditions: Stimulants Use Disorder

Interventions: Drug: dextromethorphan and memantine (DM+MM)
Drug: Placebos

First Posted Date: 2018-11-02

Last Posted Date: 2020-12-10

Lead Sponsor: Tzu-Yun Wang

Target Recruit Count: 85

Registration Number: NCT03729128

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

Drug Interaction Study of CT1812 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CT1812
Drug: tolbutamide
Drug: dextromethorphan
Drug: Omeprazole
Drug: midazolam

First Posted Date: 2018-10-23

Last Posted Date: 2018-10-23

Lead Sponsor: Cognition Therapeutics

Target Recruit Count: 16

Registration Number: NCT03716427

Locations: 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States

A Pilot Study: a Non-opioid Technique for Postoperative Adenoidectomy Pain Relief in Pediatric Patients

Phase 2

Completed

Conditions: Adenoid Hypertrophy

Interventions: Drug: Dextromethorphan
Drug: Acetaminophen
Drug: Dexmedetomidine
Drug: Ketamine

First Posted Date: 2018-10-22

Last Posted Date: 2021-02-05

Lead Sponsor: Arlyne Thung

Target Recruit Count: 10

Registration Number: NCT03714919

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

Dextromethorphan in Fibromyalgia

Phase 2

Completed

Conditions: Fibromyalgia

Interventions: Drug: Placebo
Drug: Dextromethorphan

First Posted Date: 2018-05-25

Last Posted Date: 2022-08-26

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 27

Registration Number: NCT03538054

Locations: 🇺🇸
University of Alabama of Birmingham, Birmingham, Alabama, United States

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

Phase 3

Completed

Conditions: Abortion in First Trimester

Interventions: Drug: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Drug: Dextromethorphan Hydrobromide
Drug: Oxycodone

First Posted Date: 2018-03-27

Last Posted Date: 2020-08-06

Lead Sponsor: Study Investigator-Sponsor

Target Recruit Count: 156

Registration Number: NCT03480009

Locations: 🇺🇸
Center for Family Planning Research, Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Planned Parenthood of Western Pennsylvania, Pittsburgh, Pennsylvania, United States

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Phase 1

Terminated

Conditions: Crohn Disease
Ulcerative Colitis

Interventions: Drug: Midazolam 2 mg
Drug: Ustekinumab IV Infusion
Drug: Ustekinumab SC Injection
Drug: Warfarin 10 mg
Drug: Vitamin K 10 mg
Drug: Dextromethorphan 30 mg
Drug: Omeprazole 20 mg
Drug: Caffeine 100 mg

First Posted Date: 2017-12-02

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 28

Registration Number: NCT03358706

Locations: 🇧🇪
Ghent University Hospital, Gent, Belgium
🇧🇪
Az Sint-Maarten, Mechelen, Belgium
🇬🇧
Royal Liverpool University Hospital, Liverpool, United Kingdom

and more 13 locations